中期11C-甲硫氨酸PET/CT在原发性中枢神经系统淋巴瘤中的预后意义
这项前瞻性研究纳入26例新诊断的原发性中枢神经系统淋巴瘤(PCNSL)免疫功能正常患者,在诊断时及4周期大剂量甲氨蝶呤为基础诱导化疗后行脑MRI和11C-甲硫氨酸(C-MET)PET/CT,用肿瘤/正常组织(T/N)比值和MTV评估中期反应。中位随访21个月,基于T/N比值和MTV的中期C-MET PET/CT评估分别预测无进展生存和总生存;高中期T/N比值与无进展生存降低显著相关(HR 3.68,P=0.044)。
要点
- 26例PCNSL患者诱导化疗4周期后行中期C-MET PET/CT,用T/N比值和MTV评估反应。
- 中位随访21个月,中期T/N比值和MTV分别预测无进展生存和总生存。
- 高中期T/N比值与无进展生存降低显著相关(HR 3.68,P=0.044)。
核心结论
- 基于中期C-MET PET/CT的反应评估可预测PCNSL的治疗结局。
研究设计与样本
- 前瞻性研究纳入26例新诊断的免疫功能正常PCNSL患者。
- 在诊断时及4周期大剂量甲氨蝶呤为基础诱导化疗后行脑MRI和C-MET PET/CT。
- 用肿瘤/正常组织(T/N)比值和MTV评估中期反应。
主要发现
- 所有患者均为弥漫大B细胞淋巴瘤。
- 国际结外淋巴瘤研究组各组间初始肿瘤体积或定量摄取无差异。
- 较高的国际结外淋巴瘤研究组风险评分与较高的中期MTV和T/N比值中位值及不良结局相关。
- 中位随访21个月,基于定量T/N比值和MTV的中期C-MET PET/CT评估分别预测无进展生存和总生存。
- 高中期T/N比值与无进展生存降低显著相关(HR 3.68,P=0.044)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Primary central nervous system lymphoma (PCNSL) has a poor prognosis. There has been limited study evaluating the role of interim PET/CT in PCNSL. This prospective study investigated the interim response using sequential brain PET/CT with C-methionine (C-MET) to provide prognostic information during the treatment of PCNSL. MATERIALS AND METHODS: A total of 26 immunocompetent patients recently diagnosed with PCNSL were evaluated. Brain MRI and C-MET PET/CT were performed at the time of diagnosis and after 4 cycles of high-dose methotrexate-based induction chemotherapy. Tumor-to-normal tissue (T/N) ratio and MTV were used to assess the interim response. RESULTS: All patients had diffuse large B-cell lymphoma. No differences were observed in initial tumor volume or quantitative uptake among the International Extranodal Lymphoma Study Group groups. Higher International Extranodal Lymphoma Study Group risk scores were associated with higher median values for interim MTV and T/N ratios, as well as poor outcomes. After a median follow-up of 21 months, interim C-MET PET/CT assessments based on the quantitative T/N ratio and MTV predicted progression-free survival and overall survival, respectively. A high interim T/N ratio was significantly associated with decreased progression-free survival (hazards ratio, 3.68; P = 0.044). CONCLUSIONS: Response assessments based on interim C-MET PET/CT could predict the therapeutic outcome of PCNSL.
引用
- Ahn SY, Kwon SY, Jung SH, et al. Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma. Clin Nucl Med. 2018. PMID: 29877882. doi:10.1097/RLU.0000000000002154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。